• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

钼靶筛查的参与和检出模式在预测乳腺癌生存中的作用——是否具有附加的预后价值?

The role of mammography screening attendance and detection mode in predicting breast cancer survival-is there added prognostic value?

机构信息

Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.

出版信息

Cancer Epidemiol. 2011 Dec;35(6):545-50. doi: 10.1016/j.canep.2011.02.008. Epub 2011 Apr 5.

DOI:10.1016/j.canep.2011.02.008
PMID:21470933
Abstract

INTRODUCTION

The aim of this study was to examine whether screening exposure status, defined as detection mode (screening, interval or symptomatic) combined with breast cancer screening attendance prior to diagnosis, had any additional value over detection mode in predicting breast cancer survival. We also assessed the effect of hormone replacement therapy (HRT) on the association of detection mode with breast cancer survival.

METHODS

We analysed and compared the associations of both screening exposure status and detection mode with 5-year breast cancer survival on a cohort of 3013 breast cancer patients, aged 50-74 years in Sweden. We used Cox proportional hazards modelling with adjustments for tumour size, grade, estrogen receptor (ER) and progesterone receptor (PR) status and lymph node involvement. We repeated the analyses after stratification for HRT use.

RESULTS

Multivariate hazard ratios (HR) for cancers detected in patients at subsequent screens, interval cancers and symptomatic cancers in patients with and without previous screening attendance were 1.3 (95%CI 0.7-2.3), 1.8 (95%CI 1.0-3.2), 1.8 (95%CI 0.9-3.6) and 2.2 (95%CI 1.2-4.1) respectively, compared with cancers detected at the first screen. The regression model including screening exposure status had no additional prognostic value over the model including detection mode (P=0.63). HRT users showed a more favourable survival than non-users; this was not influenced by detection mode.

CONCLUSION

The number of routine screening examinations attended in the 5-year period prior to diagnosis had no additional prognostic value over detection mode in predicting breast cancer survival.

摘要

简介

本研究旨在探讨在预测乳腺癌生存方面,筛查暴露状态(定义为检测模式[筛查、间隔或症状性]与诊断前的乳腺癌筛查参与情况相结合)是否比检测模式具有额外价值。我们还评估了激素替代疗法(HRT)对检测模式与乳腺癌生存之间关联的影响。

方法

我们分析并比较了 3013 例瑞典 50-74 岁乳腺癌患者的筛查暴露状态和检测模式与 5 年乳腺癌生存的关联。我们使用 Cox 比例风险模型,对肿瘤大小、分级、雌激素受体(ER)和孕激素受体(PR)状态以及淋巴结受累情况进行了调整。我们在分层 HRT 使用情况后重复了分析。

结果

在有或没有既往筛查参与的患者中,后续筛查、间隔期癌症和症状性癌症中检测到的癌症的多变量危险比(HR)分别为 1.3(95%CI 0.7-2.3)、1.8(95%CI 1.0-3.2)、1.8(95%CI 0.9-3.6)和 2.2(95%CI 1.2-4.1),与首次筛查中检测到的癌症相比。包括筛查暴露状态的回归模型与包括检测模式的模型相比,没有额外的预后价值(P=0.63)。HRT 使用者的生存情况优于非使用者;这不受检测模式的影响。

结论

在诊断前的 5 年内接受的常规筛查检查次数与预测乳腺癌生存方面,没有比检测模式具有额外的预后价值。

相似文献

1
The role of mammography screening attendance and detection mode in predicting breast cancer survival-is there added prognostic value?钼靶筛查的参与和检出模式在预测乳腺癌生存中的作用——是否具有附加的预后价值?
Cancer Epidemiol. 2011 Dec;35(6):545-50. doi: 10.1016/j.canep.2011.02.008. Epub 2011 Apr 5.
2
Tumour-related factors and prognosis in breast cancer detected by screening.筛查检出的乳腺癌的肿瘤相关因素和预后。
Br J Surg. 2012 Jan;99(1):78-87. doi: 10.1002/bjs.7757. Epub 2011 Nov 8.
3
Hormone replacement therapy and mammographic screening outcomes in Western Australia.西澳大利亚州的激素替代疗法与乳房X光筛查结果
J Med Screen. 2006;13(2):93-7. doi: 10.1258/096914106777589588.
4
Mode of detection: an independent prognostic factor for women with breast cancer.检测方式:乳腺癌女性患者的一个独立预后因素。
J Med Screen. 2016 Jun;23(2):89-97. doi: 10.1177/0969141315604006. Epub 2015 Nov 17.
5
Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients.孕激素受体是与乳腺癌患者临床结局和辅助他莫昔芬治疗效果相关的重要因素。
Breast Cancer Res Treat. 2010 Jan;119(1):53-61. doi: 10.1007/s10549-009-0318-0. Epub 2009 Feb 10.
6
Comparison of clinical-pathologic characteristics and outcomes of true interval and screen-detected invasive breast cancer among participants of a Canadian breast screening program: a nested case-control study.比较加拿大乳腺筛查项目参与者中真正的间期和筛查发现的浸润性乳腺癌的临床病理特征和结局:一项巢式病例对照研究。
Clin Breast Cancer. 2011 Mar;11(1):27-32. doi: 10.3816/CBC.2011.n.005.
7
Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients.在984名乳腺癌患者中,与从未使用过激素替代疗法的患者相比,在乳腺癌诊断前使用激素替代疗法可显著降低总体死亡率。
Br J Cancer. 1999 Jul;80(9):1453-8. doi: 10.1038/sj.bjc.6690543.
8
Use of hormone replacement therapy (HRT) and survival following breast cancer diagnosis.激素替代疗法(HRT)的使用与乳腺癌诊断后的生存率
Breast. 2005 Jun;14(3):192-200. doi: 10.1016/j.breast.2004.08.018. Epub 2005 Jan 8.
9
Interval breast cancers: prognostic features and survival by subtype and time since screening.间期乳腺癌:按亚型及自筛查以来的时间划分的预后特征与生存情况
J Med Screen. 2006;13(3):115-22. doi: 10.1258/096914106778440572.
10
Socioeconomic inequalities in attending the mass screening for breast cancer in the south of the Netherlands--associations with stage at diagnosis and survival.荷兰南部参加乳腺癌大规模筛查的社会经济不平等现象-与诊断时的分期和生存的关联。
Breast Cancer Res Treat. 2011 Jul;128(2):517-25. doi: 10.1007/s10549-011-1363-z. Epub 2011 Feb 3.

引用本文的文献

1
Impact of Overdiagnosis on Long-Term Breast Cancer Survival.过度诊断对乳腺癌长期生存的影响。
Cancers (Basel). 2019 Mar 7;11(3):325. doi: 10.3390/cancers11030325.
2
Observed and Predicted Risk of Breast Cancer Death in Randomized Trials on Breast Cancer Screening.随机乳腺癌筛查试验中观察到的和预测的乳腺癌死亡风险。
PLoS One. 2016 Apr 21;11(4):e0154113. doi: 10.1371/journal.pone.0154113. eCollection 2016.
3
Reduction in interval cancer rates following the introduction of two-view mammography in the UK breast screening programme.
英国乳房筛查计划引入双视图乳房 X 光摄影后,间隔期癌症发病率降低。
Br J Cancer. 2014 Feb 4;110(3):560-4. doi: 10.1038/bjc.2013.778. Epub 2013 Dec 24.
4
Molecular profiles of screen detected vs. symptomatic breast cancer and their impact on survival: results from a clinical series.筛查性与症状性乳腺癌的分子特征及其对生存的影响:一项临床系列研究结果。
BMC Cancer. 2013 Jan 10;13:15. doi: 10.1186/1471-2407-13-15.
5
Breast cancer screening: evidence of benefit depends on the method used.乳腺癌筛查:获益证据取决于所使用的方法。
BMC Med. 2012 Dec 12;10:163. doi: 10.1186/1741-7015-10-163.